Cost and health related quality of life consequences of multiple sclerosis

被引:59
作者
Grima, DT
Torrance, GW
Francis, G
Rice, G
Rosner, AJ
Lafortune, L
机构
[1] McMaster Univ, Hamilton, ON, Canada
[2] Montreal Neurol Inst, Montreal, PQ, Canada
[3] Hlth Util Inc, Dundas, ON, Canada
[4] London Hlth Sci Ctr, London, ON N6A 5A5, Canada
[5] Hoechst Marion Roussel Canada Res Inc, Laval, PQ H7L 4A8, Canada
关键词
multiple sclerosis; quality of life; costs; patient survey; chart review; Canada;
D O I
10.1191/135245800678827545
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To (i) quantify the cost of multiple sclerosis (MS) to the Canadian health care system and society; (ii) measure health utility in MS patients, and (iii) examine the influence of disability on patient utility and health core costs. Materials and methods: A comprehensive patient survey and chart review of relapsing MS patients in remission, relapse and recalling a relapse. Results: Annual remission costs increased with EDSS level ($7596 at EDSS 1, $33 206 at EDSS 6). At all EDSS levels the largest costs were due to inability to work, which increased with EDSS. The average relapse cost for all EDSS levels was $1367. An inverse correlation was found between EDSS level and patient utility for patients in remission and relapse. The decrease in remission health utility from EDSS 1 to 6 was 0.24, which is 25% greeter than the difference in health status between on average 25 and 85 year-old Conclusions: This study demonstrates that MS Produces substantial health core costs and reductions in patient quality of life end ability to work, losses that con be avoided or delayed if disease Progression is slowed. These data provide health-care decision-makers with the opportunity to consider the full impact of MS when faced with budget allocation decisions.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 31 条
  • [1] Economic consequences of multiple sclerosis for Canadians
    Asche, CV
    Ho, E
    Chan, B
    Coyte, PC
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (05): : 268 - 274
  • [2] Auty A, 1998, CAN J NEUROL SCI, V25, P23
  • [3] Barr RD, 1997, INT J ONCOL, V11, P333
  • [4] Cannell CharlesF., 1981, SOCIOL METHODOL, V12, P389, DOI [DOI 10.2307/270748, 10.2307/270748]
  • [5] COMPSTON A, 1994, BAILLIERE CLIN NEUR, V3, P353
  • [6] MULTIATTRIBUTE HEALTH-STATUS CLASSIFICATION SYSTEMS - HEALTH UTILITIES INDEX
    FEENY, D
    FURLONG, W
    BOYLE, M
    TORRANCE, GW
    [J]. PHARMACOECONOMICS, 1995, 7 (06) : 490 - 502
  • [7] Feeny D., 1996, QUALITY LIFE PHARMAC, P239
  • [8] FEENY DH, 1996, QUALITY LIFE PHARMAC, P249
  • [9] *HAM, 1907, MULT SCLER, P97
  • [10] *HAM HLTH SCI CORP, 1997, CHED MCM HOSP